Janssen doesn't seem to be in much of a hurry to get latest trial info out to the public...we started infusing for IMBark back in October 6 months ago. With IMET's fast acting capabilities to quote your Irish trader we should have seen sustainable results months ago,
old pine box why doth thou beckon me? I am not quite ready to lie down and rest ethernal
why would you be pumping to buy just bfr an obvious lower earnings report coming up next week joko? No $35mil upfront booked this QRT
joko you & your aliases have been the pure evil deceivers for 2 solid years now. Anyone following your constant pumping advice would have lost most of their investment by not selling peaks. Unless you are constantly trading here you will lose any gains. Your hedge fund has posted their February $2.81 signal support and by joko they'll get it there again after earnings is announced next week.They have Chippy's blessing.
SP hit $3.34 yesterday. Today closed at $3.11....where is the short meltdown with a 23 cent drop?
well at least he never paid for one share like you and I did. He's the fox in this chicken coup called GERN.
with our measly million or so vote doubt Chipster will see the dumpster anytime soon. Meanwhile we sit and watch ANOTHER low volume take down. They didn't waste any time bringing it down this time.
proof is in the SP
if this hedge fund wasn't running the SP you would expect a proxy rally close to last year's SP gain
seems like the lid has been left on for this year
the last big thief in the night I experienced was Chip's FDA hold announcement 6 am EST March 10, 2014
SRPT shares down over 54% on news
The advisory committee voted 6-7 against the finding of substantial evidence from adequate and well controlled studies that show that eteplirsen induces production of dystrophin to a level that is reasonably likely to predict clinical benefit.
The advisory committee voted 3 -- 7, with three abstentions, against finding substantial evidence based on the clinical results of the single historically controlled study that eteplirsen is effective for treatment of DMD.
In three additional voting questions, the panel voted 5 to 7, with one abstention, against whether decisions to administer the 6-minute walk test (vs. conclusions that the patient could no longer walk) were sufficiently objective and free of bias and subjective decision-making by patients, their caregivers, and/or health care professionals to allow for a valid comparison between patients in Study201/202 and an external control group
Briefing note: The FDA is not bound by the Advisory Committee's recommendation but takes its advice into consideration when reviewing New Drug and Biologic License Applications in general.
well lets see last week it was AACR 2016
Abstract Number: 2731 for a 2 cent SP increase
ASCO for ?
until this hedge fund that is playing GERN ceases and desists to actively short any nominal gain back to it's previous level we will go no where on SP here.
today's HF put signal is 200 bids on $2.81
That's where they'll take this before June's AACR presentation.